The FDA on December 1, 2022, approved REZLIDHIA® (Olutasidenib) capsules for adult patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. REZLIDHIA® is a product of Rigel Pharmaceuticals, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
